RANKing c-Jun in osteoclast development.
作者信息
Teitelbaum Steven L
机构信息
Department of Pathology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA.
出版信息
J Clin Invest. 2004 Aug;114(4):463-5. doi: 10.1172/JCI22644.
Abstract
Pathological bone loss always reflects enhanced net osteoclastic activity. Recognition and binding of the receptor activator of NF-κB (RANK) by RANK ligand (RANKL) is the key osteoclastogenic event, and the signaling cascades induced by this reaction therefore contain potential anti-osteoporosis therapeutic targets. A study reported in this issue of the documents that a pivotal component of RANKL/RANK-mediated osteoclast recruitment involves sequential induction of the transcription factors c-Jun and nuclear factor of activated T cells 2 .
摘要
相似文献
1
RANKing c-Jun in osteoclast development.
J Clin Invest. 2004 Aug;114(4):463-5. doi: 10.1172/JCI22644.
2
RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis.
EMBO J. 2005 Feb 23;24(4):790-9. doi: 10.1038/sj.emboj.7600564. Epub 2005 Jan 27.
3
TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
J Bone Miner Res. 2005 May;20(5):840-7. doi: 10.1359/JBMR.041225. Epub 2004 Dec 20.
4
Signal transduction pathways regulating osteoclast differentiation and function.
J Bone Miner Metab. 2003;21(3):123-33. doi: 10.1007/s007740300021.
5
Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.
Biochem Biophys Res Commun. 2005 Apr 15;329(3):839-45. doi: 10.1016/j.bbrc.2005.02.049.
6
Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation.
Nat Genet. 2000 Feb;24(2):184-7. doi: 10.1038/72855.
7
RANK-L induces the expression of NFATc1, but not of NFkappaB subunits during osteoclast formation.
Biochem Biophys Res Commun. 2005 Jan 7;326(1):131-5. doi: 10.1016/j.bbrc.2004.10.212.
8
Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells.
Bone. 2007 Oct;41(4):592-602. doi: 10.1016/j.bone.2007.05.016. Epub 2007 Jun 13.
9
Dimer formation of receptor activator of nuclear factor kappaB induces incomplete osteoclast formation.
Biochem Biophys Res Commun. 2004 Dec 3;325(1):229-34. doi: 10.1016/j.bbrc.2004.10.024.
10
Flavonoid quercetin decreases osteoclastic differentiation induced by RANKL via a mechanism involving NF kappa B and AP-1.
J Cell Biochem. 2004 May 15;92(2):285-95. doi: 10.1002/jcb.20071.
引用本文的文献
1
Ginsenoside Rg2 inhibits osteoclastogenesis by downregulating the NFATc1, c-Fos, and MAPK pathways.
BMB Rep. 2023 Oct;56(10):551-556. doi: 10.5483/BMBRep.2023-0100.
2
Biological mechanism of surgery-mediated acceleration of orthodontic tooth movement: A narrative review.
J Int Med Res. 2022 Sep;50(9):3000605221123904. doi: 10.1177/03000605221123904.
3
Protein phosphatase 1 regulatory subunit 18 suppresses the transcriptional activity of NFATc1 via regulation of c-fos.
Bone Rep. 2021 Aug 4;15:101114. doi: 10.1016/j.bonr.2021.101114. eCollection 2021 Dec.
4
6-Shogaol promotes bone resorption and accelerates orthodontic tooth movement through the JNK-NFATc1 signaling axis.
J Bone Miner Metab. 2021 Nov;39(6):962-973. doi: 10.1007/s00774-021-01245-y. Epub 2021 Jun 30.
5
Puerarin Exerts Protective Effects on Wear Particle-Induced Inflammatory Osteolysis.
Front Pharmacol. 2019 Oct 1;10:1113. doi: 10.3389/fphar.2019.01113. eCollection 2019.
6
Water Extracts of Hull-less Waxy Barley ( L.) Cultivar 'Boseokchal' Inhibit RANKL-induced Osteoclastogenesis.
Molecules. 2019 Oct 16;24(20):3735. doi: 10.3390/molecules24203735.
7
Egg White Ovotransferrin Attenuates RANKL-Induced Osteoclastogenesis and Bone Resorption.
Nutrients. 2019 Sep 19;11(9):2254. doi: 10.3390/nu11092254.
8
Formononetin Regulates Multiple Oncogenic Signaling Cascades and Enhances Sensitivity to Bortezomib in a Multiple Myeloma Mouse Model.
Biomolecules. 2019 Jul 7;9(7):262. doi: 10.3390/biom9070262.
9
Propofol promotes osteoclastic bone resorption by increasing DC-STAMP expression.
J Dent Anesth Pain Med. 2018 Dec;18(6):349-359. doi: 10.17245/jdapm.2018.18.6.349. Epub 2018 Dec 28.
10
I-BET151 suppresses osteoclast formation and inflammatory cytokines secretion by targetting BRD4 in multiple myeloma.
Biosci Rep. 2019 May 14;39(5). doi: 10.1042/BSR20181245. Print 2019 May 31.
本文引用的文献
1
Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation.
J Clin Invest. 2004 Aug;114(4):475-84. doi: 10.1172/JCI19657.
2
Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects.
J Cell Biol. 2004 Feb 16;164(4):613-23. doi: 10.1083/jcb.200308155. Epub 2004 Feb 9.
3
Osteoclast differentiation and activation.
Nature. 2003 May 15;423(6937):337-42. doi: 10.1038/nature01658.
4
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women.
J Clin Invest. 2003 Apr;111(8):1221-30. doi: 10.1172/JCI17215.
5
Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts.
Dev Cell. 2002 Dec;3(6):889-901. doi: 10.1016/s1534-5807(02)00369-6.
6
JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms.
J Cell Sci. 2002 Nov 15;115(Pt 22):4317-25. doi: 10.1242/jcs.00082.
7
Regulation of the murine Nfatc1 gene by NFATc2.
J Biol Chem. 2002 Mar 22;277(12):10704-11. doi: 10.1074/jbc.M107068200. Epub 2002 Jan 10.
8
Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity.
J Clin Invest. 2001 Oct;108(7):971-9. doi: 10.1172/JCI13890.
9
Partners in transcription: NFAT and AP-1.
Oncogene. 2001 Apr 30;20(19):2476-89. doi: 10.1038/sj.onc.1204386.
10
Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation.
J Biol Chem. 2001 Mar 23;276(12):8836-40. doi: 10.1074/jbc.M010764200. Epub 2000 Dec 19.
Zotero 插件